Please assess the completion status of the following clinical trial:

Trial Title: Fondaparinux 1,5 mg for the Prevention of Venous Thromboembolism (VTE) in Medical Patients With Renal Insufficiency

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 60 years~* Acute medical disease requiring thromboprophylaxis according to international guidelines~* Anticipated immobilization of at least 4 days~* Renal insufficiency defined by creatinine clearance between 20 and 50 mL/min according the MDRD formula~* Written informed consent~Exclusion Criteria:~* Active bleeding or bleeding in the previous 3 months~* Known bleeding diathesis~* Platelet count \< 100.000~* Ongoing treatment with unfractionated heparin, low molecular weight heparin, fondaparinux, or vitamin K antagonists~* Use of prophylactic doses of heparin, low molecular weight heparin, or fondaparinux in the previous 72 hours~* Life expectancy \< 1 month

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- fondaparinux (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).